<?xml version='1.0' encoding='utf-8'?>
<document id="27507037"><sentence text="Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors."><entity charOffset="70-80" id="DDI-PubMed.27507037.s1.e0" text="irinotecan" /></sentence><sentence text="The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug-drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI)"><entity charOffset="138-148" id="DDI-PubMed.27507037.s2.e0" text="irinotecan" /><entity charOffset="198-210" id="DDI-PubMed.27507037.s2.e1" text="folinic acid" /><entity charOffset="215-229" id="DDI-PubMed.27507037.s2.e2" text="5-fluorouracil" /><entity charOffset="231-238" id="DDI-PubMed.27507037.s2.e3" text="FOLFIRI" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e0" e2="DDI-PubMed.27507037.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e0" e2="DDI-PubMed.27507037.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e0" e2="DDI-PubMed.27507037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e0" e2="DDI-PubMed.27507037.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e1" e2="DDI-PubMed.27507037.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e1" e2="DDI-PubMed.27507037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e1" e2="DDI-PubMed.27507037.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e2" e2="DDI-PubMed.27507037.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27507037.s2.e2" e2="DDI-PubMed.27507037.s2.e3" /></sentence><sentence text="" /><sentence text="Patients received intravenous infusions of FOLFIRI and ramucirumab 8 mg/kg on Day 1 of a 2-week cycle" /><sentence text=" FOLFIRI was administered alone in Cycle 1; ramucirumab followed by FOLFIRI was administered in all subsequent cycles" /><sentence text=" Blood was collected at regular intervals after infusions in Cycles 1 and 2 to determine irinotecan, SN-38, and ramucirumab concentrations"><entity charOffset="89-99" id="DDI-PubMed.27507037.s6.e0" text="irinotecan" /><entity charOffset="101-106" id="DDI-PubMed.27507037.s6.e1" text="SN-38" /><entity charOffset="112-123" id="DDI-PubMed.27507037.s6.e2" text="ramucirumab" /><pair ddi="false" e1="DDI-PubMed.27507037.s6.e0" e2="DDI-PubMed.27507037.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27507037.s6.e0" e2="DDI-PubMed.27507037.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27507037.s6.e0" e2="DDI-PubMed.27507037.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27507037.s6.e1" e2="DDI-PubMed.27507037.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27507037.s6.e1" e2="DDI-PubMed.27507037.s6.e2" /></sentence><sentence text=" PK parameters were derived by noncompartmental analysis" /><sentence text="" /><sentence text="Twenty-nine patients received treatment" /><sentence text=" The dose-normalized area under the concentration versus time curve from zero to infinity [AUC(0-∞)] and the maximum observed concentration (C max) of irinotecan and SN-38 were comparable between Cycle 1 (FOLFIRI alone) and Cycle 2 (ramucirumab + FOLFIRI)"><entity charOffset="151-161" id="DDI-PubMed.27507037.s10.e0" text="irinotecan" /><entity charOffset="166-175" id="DDI-PubMed.27507037.s10.e1" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.27507037.s10.e0" e2="DDI-PubMed.27507037.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27507037.s10.e0" e2="DDI-PubMed.27507037.s10.e1" /></sentence><sentence text=" The ratios of geometric least squares (LS) means for irinotecan were 0" /><sentence text="93 (90 % CI 0" /><sentence text="83-1" /><sentence text="05) for AUC(0-∞) and 1" /><sentence text="04 (90 % CI 0" /><sentence text="97-1" /><sentence text="12) for C max" /><sentence text=" The ratios of geometric LS means for SN-38 were 0"><entity charOffset="38-42" id="DDI-PubMed.27507037.s18.e0" text="SN-38" /></sentence><sentence text="95 (90 % CI 0" /><sentence text="88-1" /><sentence text="04) for AUC(0-∞) and 0" /><sentence text="97 (90 % CI 0" /><sentence text="85-1" /><sentence text="12) for C max" /><sentence text=" The most common treatment-emergent adverse events, regardless of grade, were fatigue (19 patients, 65" /><sentence text="5 %), diarrhea, (16 patients, 55" /><sentence text="2 %), and neutropenia (15 patients, 51" /><sentence text="7 %)" /><sentence text=" Grade ≥3 neutropenia was reported in 7 (24" /><sentence text="1 %) patients" /><sentence text="" /><sentence text="There was no PK drug-drug interaction between ramucirumab and irinotecan or its metabolite, SN-38"><entity charOffset="62-72" id="DDI-PubMed.27507037.s32.e0" text="irinotecan" /><entity charOffset="92-101" id="DDI-PubMed.27507037.s32.e1" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.27507037.s32.e0" e2="DDI-PubMed.27507037.s32.e0" /><pair ddi="false" e1="DDI-PubMed.27507037.s32.e0" e2="DDI-PubMed.27507037.s32.e1" /></sentence><sentence text=" Ramucirumab with FOLFIRI was well tolerated in this study, with no new safety concerns" /><sentence text="" /></document>